Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects.

Massimo TempestilliTommaso Ascoli BartoliDomenico BenvenutoGiulia Valeria StaziLuisa MarchioniEmanuele NicastriChiara Agrati

Published in: The Journal of antimicrobial chemotherapy (2022)

Our results showed a high interpatient variability of remdesivir and GS-441524 likely due to both age and renal function in COVID-19 inpatients. Further research is required to understand whether the pharmacokinetics of remdesivir and its metabolites may influence drug-related efficacy or toxic effect.

Keyphrases

coronavirus disease
sars cov
ms ms
emergency department
drug induced
adverse drug
newly diagnosed